Heterogeneity of pathological tumour response in patients with multiple colorectal liver metastases undergoing resection after preoperative chemotherapy [0.03%]
异时性多发结直肠肝转移患者新辅助化疗后手术切除标本的病理反应异质性分析
R Akpinar,A Ammirabile,C Piombo et al.
R Akpinar et al.
Background: Pathological tumour response to preoperative chemotherapy is a key prognostic factor in patients with colorectal liver metastases (CRLM). Multiple CRLM may present different responses, but the prognostic signi...
Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study [0.03%]
一项Ib期研究（CodeBreaK 101）：sotorasib联合帕尼单抗和FOLFIRI治疗既往接受过治疗的携带KRAS G12C突变的转移性结直肠癌患者的安全性和疗效
T Masuishi,J H Strickler,Y Kuboki et al.
T Masuishi et al.
Background: In the phase III CodeBreaK 300 trial (NCT05198934), the combination of sotorasib, a KRASG12C inhibitor, and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic ...
Clinical Trial
ESMO open. 2026 Sep;11(9):108338. DOI:10.1016/j.esmoop.2026.108338 2026
Paclitaxel oral solution versus paclitaxel injection as second-line therapy for advanced gastric cancer: a multicenter, open-label, randomized phase III trial [0.03%]
口服紫杉醇与注射用紫杉醇治疗晚期胃癌二线患者的多中心开放随机Ⅲ期临床研究
J Li,M Huang,T Deng et al.
J Li et al.
Background: Paclitaxel is widely used in various cancers. This study aimed to evaluate paclitaxel oral solution versus paclitaxel injection in the second line of gastric cancer. ...
Clinical Trial
ESMO open. 2026 Sep;11(9):108312. DOI:10.1016/j.esmoop.2026.108312 2026
Circulating tumor DNA dynamics in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer assessed using an ultrasensitive tumor-informed assay [0.03%]
利用超灵敏肿瘤特异性血液ctDNA检测评估激素受体阳性/her2阴性早期乳腺癌患者血浆中ctDNA动态变化
C H Barcenas,A Contreras,A Alexander et al.
C H Barcenas et al.
Background: Circulating tumor DNA (ctDNA) in early breast cancer (EBC) is prognostic for distant relapses. The ctDNA dynamics in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative EBC,...
Time-dependent prognostic impact of tumor grade in stage I-III breast cancers [0.03%]
I-III期乳腺癌中肿瘤分级的预后价值及时间依赖性
M Mariani,M Ochocki,G Bianchini et al.
M Mariani et al.
Background: Breast cancer (BC) mortality risk extends over decades; yet, the temporal prognostic patterns of histological grade across subtypes and stages remain unclear. ...
Homologous recombination deficiency testing implementation in the routine clinical setting: real-life experience and lessons learned [0.03%]
同源重组缺陷检测在常规临床应用中的实践经验与教训
P Romero-Lozano,M Gómez-Rey,M Vila-Casadesús et al.
P Romero-Lozano et al.
Background: Homologous recombination deficiency (HRD) is a critical biomarker for predicting response to poly (ADP-ribose) polymerase (PARP) inhibitors in high-grade serous ovarian cancer (HGSOC). Hence, genomic scar-base...
Advancing breast cancer clinical management through technological innovation: the potential role of artificial intelligence and integrated care models [0.03%]
通过技术创新推进乳腺癌临床管理：人工智能和整合护理模式的潜在作用
A Toss,L Bellardita,A Botticelli et al.
A Toss et al.
In health care, artificial intelligence (AI) is emerging as a powerful tool to improve the quality of care, support health care professionals, and build a more streamlined and efficient health care system while also enhancing the patient ex...
Advancing breast cancer clinical management through technological innovation: the potential role of artificial intelligence and integrated care models [0.03%]
通过技术创新推进乳腺癌临床管理：人工智能和整合护理模式的潜在作用
A Toss,L Bellardita,A Botticelli et al.
A Toss et al.
In health care, artificial intelligence (AI) is emerging as a powerful tool to improve the quality of care, support health care professionals, and build a more streamlined and efficient health care system while also enhancing the patient ex...
Maintenance rucaparib after first-line platinum-based chemotherapy in HER2-negative advanced oesophagogastric adenocarcinoma: results from the PLATFORM study [0.03%]
铂类化疗后鲁卡帕尼维持治疗HER2阴性的晚期胃食管腺癌：来自PLATFORM研究的结果
A Gordon,C Fong,L Satchwell et al.
A Gordon et al.
Background: PLATFORM is a prospective, open-label, multicentre, adaptive phase II trial assessing maintenance therapy in patients with advanced HER2-negative oesophagogastric adenocarcinoma after platinum-based first-line...
HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility [0.03%]
早期HER2阳性乳腺癌中HER2 DX的临床应用回顾
S M Tolaney,N Tung,A C Wolff et al.
S M Tolaney et al.
Therapies targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer have substantially improved outcomes. Nevertheless, marked biological and clinical heterogeneity continue to drive variability in prognosis and treat...